Posology News and Research

RSS
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment